Unique Surface Structures on Synovial Cells
Unique Surface Structures on Synovial Cells
批准号:
6738962
负责人:
David Alan Fox
金额:
$28.76万
依托单位国家:
美国
项目类别:
财政年份:
1986
资助国家:
美国
项目状态:
已结题
起止时间:
1986-08-01 至 2007-03-31
关键词:
CD antigensT lymphocyteapoptosisbiomarkercell adhesion moleculescell cell interactioncell morphologyclinical researchcytokinedisease /disorder modelfibroblastsgene expressionhuman subjecthuman tissueleukocyte activation /transformationmicroarray technologymonoclonal antibodypatient oriented researchrheumatoid arthritissynovial membrane
中文摘要
描述(由申请方提供):类风湿性关节炎(RA)
伴随着炎症和关节结构的最终破坏
T淋巴细胞和巨噬细胞广泛浸润滑膜,
滑膜成纤维细胞(SF)增生。T淋巴细胞的作用仍然存在
有争议的,没有确凿的证据表明T细胞定向自身免疫,
因为RA。我们已经采取了几种方法来更好地了解途径,
T细胞活化和T细胞在RA中的作用,包括产生
针对新的T细胞表面抗原的单克隆抗体和表面抗原的配体,
对T细胞活化重要的结构,包括SF上表达的配体。
此外,我们已经有证据表明,T细胞,即使是静息T细胞,
以双向方式与SF交互。因此,SF可以作为有效的
辅助细胞的T细胞活化,而静息T细胞可以刺激一个
SF中的促炎基因表达模式,即使在缺乏
激活T细胞的刺激物。我们把这种未激活的T细胞的能力称为
淋巴细胞刺激静息T细胞的SF效应子功能。“我们现在
提出RA中SF的攻击行为的重要组成部分
由T细胞和RA SF之间的直接相互作用引起。我们还假设
这种不寻常的致病细胞程序的分子基础
分化起源于T细胞之间形成的独特的免疫突触,
淋巴细胞和SF。目前的建议将进一步分析分子
T细胞和SF之间的相互作用及其功能后果
相互作用,使用形态学和免疫学方法。新型配体
SF表达的CD 6的分子特征和功能
研究了将产生新的抗体来分析T细胞/SF微阵列
SF基因表达和定量相互作用的分析,针对两者
已知的和新的细胞表面分子和分泌的CD 26相关细胞
相互作用分子吸引素SF的激活将使用
测量相关RNA种类和蛋白质产物,如破骨细胞
分化因子、细胞因子和组织破坏性蛋白酶。的
拟议的研究代表了一种新的方法来了解RA。
英文摘要
DESCRIPTION (provided by the applicant): In rheumatoid arthritis (RA)
inflammation and ultimate destruction of articular structures are accompanied
by extensive infiltration of synovium by T lymphocytes and macrophages, and
hyperplasia of synovial fibroblasts (SF). The role of T lymphocytes remains
controversial, with no conclusive proof for T cell directed autoimmunity as the
cause of RA. We have taken several approaches to better understand pathways of
T cell activation and of the role of T cells in RA, including generation of
monoclonal antibodies to novel T cell surface antigens, and ligands of surface
structures important for T cell activation, including ligands expressed on SF.
In addition we have developed evidence that T cells, even resting T cells, can
interact with SF in a bi-directional manner. Thus SF can function as potent
accessory cells for T cell activation, while resting T cells can stimulate a
proinflammatory pattern of gene expression in SF, even in the absence of
stimuli that activate the T cell. We have termed this ability of unactivated T
lymphocytes to stimulate the SF "effector function of resting T cells." We now
propose that a significant component of the aggressive behavior of SF in RA
arises from direct interactions between T cells and RA SF. We also hypothesize
that the molecular basis for this unusual and pathogenic program of cell
differentiation arises from a unique immunologic synapse formed between the T
lymphocyte and the SF. The current proposal would further analyze the molecular
interactions between T cells and SF and the functional consequences of these
interactions, using both morphologic and immunologic approaches. A novel ligand
of CD6 expressed by SF will be molecularly characterized and functionally
studied. New antibodies will be generated to analyze the T cell/SF microarray
analysis of SF gene expression, and quantitative interaction, directed at both
known and novel cell surface molecules and at the secreted CD26-related cell
interaction molecule attractin. Activation of SF will be studied using
measurement of relevant RNA species and protein products, such as osteoclast
differentiation factor, cytokines, and tissue destructive proteases. The
proposed studies represent a fresh approach to understanding RA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
University of Michigan Clinical Autoimmunity Center of Excellence
-
批准号:10662184
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2019
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Clinical Autoimmunity Center of Excellence
-
批准号:9916706
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2019
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Clinical Autoimmunity Center of Excellence
-
批准号:10380100
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2019
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Clinical Autoimmunity Center of Excellence
-
批准号:10165485
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2019
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Autoimmunity Center of Excellence, Clinical Research Progr
-
批准号:8842928
-
项目类别:
-
资助金额:$7.75万
-
财政年份:2014
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Autoimmunity Center of Excellence, Clinical Research Progr
-
批准号:9480038
-
项目类别:
-
资助金额:$7.75万
-
财政年份:2014
-
负责人:David Alan Fox
-
依托单位:
Administrative Core
-
批准号:7530526
-
项目类别:
-
资助金额:$16.24万
-
财政年份:2007
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Rheumatic Diseases Core Center
-
批准号:6781096
-
项目类别:
-
资助金额:$60.13万
-
财政年份:2001
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Rheumatic Diseases Research Core Center
-
批准号:7938844
-
项目类别:
-
资助金额:$58.99万
-
财政年份:2001
-
负责人:David Alan Fox
-
依托单位:
CORE--HYBRIDOMA FACILITY
-
批准号:6416838
-
项目类别:
-
资助金额:$11.52万
-
财政年份:2001
-
负责人:David Alan Fox
-
依托单位:
CORE--HYBRIDOMA FACILITY
-
批准号:6548052
-
项目类别:
-
资助金额:$7.6万
-
财政年份:2001
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Rheumatic Diseases Research Core Center
-
批准号:7270632
-
项目类别:
-
资助金额:$59.04万
-
财政年份:2001
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Rheumatic Diseases Research Core Center
-
批准号:7483086
-
项目类别:
-
资助金额:$59.04万
-
财政年份:2001
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Rheumatic Diseases Core Center
-
批准号:6437857
-
项目类别:
-
资助金额:$51.15万
-
财政年份:2001
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Rheumatic Diseases Core Center
-
批准号:6533033
-
项目类别:
-
资助金额:$60.19万
-
财政年份:2001
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Rheumatic Diseases Core Center
-
批准号:6643583
-
项目类别:
-
资助金额:$60.27万
-
财政年份:2001
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Rheumatic Diseases Core Center
-
批准号:6942766
-
项目类别:
-
资助金额:$60.19万
-
财政年份:2001
-
负责人:David Alan Fox
-
依托单位:
University of Michigan Rheumatic Diseases Research Core Center
-
批准号:7662391
-
项目类别:
-
资助金额:$59.04万
-
财政年份:2001
-
负责人:David Alan Fox
-
依托单位:
CORE--HYBRIDOMA FACILITY
-
批准号:6299782
-
项目类别:
-
资助金额:$11.52万
-
财政年份:2000
-
负责人:David Alan Fox
-
依托单位:
CORE--HYBRIDOMA FACILITY
-
批准号:6100322
-
项目类别:
-
资助金额:$10.9万
-
财政年份:1999
-
负责人:David Alan Fox
-
依托单位:
海外基金